APOSTEL 8

• Research type

  Research Study

• Full title

  Atosiban versus placebo in the treatment of threatened preterm birth (APOSTEL 8).

• IRAS ID

  230066

• Contact name

  Marjolein Spiering

• Contact email

  apostel8@amc.nl

• Sponsor organisation

  Amsterdam UMC, location AMC

• Eudract number

  2017-001007-72

• Duration of Study in the UK

  2 years, 10 months, 0 days

• Research summary

  Theatened preterm birth complicates thousends of pregnancies annually. Tocolysis is historically a part of the treatment, but the effectiveness of the treatment has never been proven. The WHO has recently stated that the use of tocolytica should be reconsidered. The aim of this study is to investigate if tocolysis with atosiban in late preterm birth (30 to 34 weeks) is effective compared with placebo in improving neonatal morbidity and mortality.

• REC name

  East Midlands - Derby Research Ethics Committee

• REC reference

  17/EM/0248

• Date of REC Opinion

  13 Dec 2017

• REC opinion

  Further Information Favourable Opinion